semaglutide depression anxiety Study links and tirzepatide to fewer and diagnoses in obesity care GLP1-RAs linked with reduced risk

The US Food and Drug Administration (FDA) has approved Wegovy to: Reduce body weight and support long-term weight loss in people with obesity or with overweight and a weight-related health condition, such as type 2 diabetes or sleep apnea Reduce the risk of experiencing a major cardiovascular event , such as heart attack, stroke, or death, in people with heart disease and obesity or overweight Typically, healthcare providers prescribe a starting dose of 0.25 mg weekly

Drinking plenty of water can help reduce feelings of fatigue, prevent side effects such as constipation, and maintain steady energy levels

Instead of getting a semaglutide injection plus a separate B12 injection, patients receive both in one shot

Retrieved from Chruel, F., Jarlier, M., & Sancho-Garnier, H

As compared to other medications that must be administered once or twice a day, it is considered to be a long-acting option in its drug class